Valuation : Ind-Swift Laboratories Limited

Market Cap 11.4B 119M 103M 96.7M 88.29M 166M 167M 1.15B 448M 5.76B 449M 439M 19.13B P/E 2024
1.41x
P/E 2025 2.38x
Enterprise Value 7.13B 74.76M 64.55M 60.51M 55.24M 104M 104M 717M 280M 3.61B 281M 275M 11.97B EV / Sales 2024
0.14x
EV / Sales 2025 0.12x
Free-Float
36.27%
Yield 2024 *
-
Yield 2025 -
1 day+1.37%
1 week+10.22%
Current month+61.48%
1 month+53.81%
3 months+169.19%
6 months+149.57%
Current year+311.61%
1 week 317.3
Extreme 317.3
373.9
1 month 215.5
Extreme 215.5
373.9
Current year 88.5
Extreme 88.5
373.9
1 year 87
Extreme 87
373.9
3 years 67.15
Extreme 67.15
373.9
5 years 51.1
Extreme 51.1
373.9
10 years 15.25
Extreme 15.25
373.9
Manager TitleAgeSince
Chief Executive Officer 74 1995-01-03
Chief Executive Officer 44 2011-06-14
Director of Finance/CFO - 2018-09-28
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 2010-03-22
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%+10.22% - - 330M
+0.35%+0.93%+21.08%+71.89% 48.2B
-0.08%-0.21%+55.27%+121.68% 39.97B
+0.15%+6.34%+21.70%+87.77% 12.43B
+0.25%-0.61%-9.92%+15.84% 12.03B
+0.19%0.00%+30.00%+147.62% 9.35B
+0.07%+3.80%+27.45%+46.12% 7.75B
+2.24%+8.50%+29.85%+227.84% 7.43B
+0.04%+0.37%+48.15%-11.95% 7.22B
-0.53%-1.53%-34.29%+19.67% 5.3B
Average +0.40%+2.32%+21.03%+80.72% 16.63B
Weighted average by Cap. +0.24%+1.42%+28.44%+87.24%

Financials

2024 2025
Net sales 12.97B 136M 117M 110M 100M 189M 190M 1.3B 509M 6.56B 511M 499M 21.78B 5.62B 58.89M 50.85M 47.66M 43.52M 81.91M 82.26M 565M 221M 2.84B 221M 216M 9.43B
Net income 4.21B 44.13M 38.11M 35.72M 32.61M 61.39M 61.65M 423M 165M 2.13B 166M 162M 7.07B 2.5B 26.26M 22.67M 21.25M 19.4M 36.53M 36.68M 252M 98.37M 1.27B 98.59M 96.44M 4.21B
Net Debt -4.15B -43.54M -37.59M -35.24M -32.17M -60.56M -60.82M -418M -163M -2.1B -163M -160M -6.97B -4.27B -44.72M -38.61M -36.19M -33.04M -62.2M -62.47M -429M -168M -2.16B -168M -164M -7.16B
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,246
Date Price Change Volume
26-08-28 ₹363.00 +1.37% 36,839
26-08-27 ₹358.10 -2.62% 53,634
26-08-26 ₹367.75 +13.35% 226,396
26-08-25 ₹324.45 -0.86% 32,208
26-08-24 ₹327.25 -0.64% 27,590